The advent of the new revolutionary approach based on regenerative medicine is progressively reshaping the therapeutic scenario of many different diseases, such as cardiovascular diseases and immune diseases, with encouraging results. During the last 10 years, many studies have also proposed the use of mesenchymal stem cells (MSCs), adult stem cells with several interesting properties already used in different experimental models, for the treatment of diabetes, however, reporting conflicting outcomes. These reasons have given rise to a question: are these cells a real trump card for the biomedical field? Are they really able to outclass the traditional therapies, or at least able to give an advantage ove them? In this review, we will discuss the most promising results obtained with MSCs for the treatment of diabetes and its complications, we will compare the different therapeutic treatments applied as well as the most likely mechanisms of action, and overall we will give an in-depth overview of the pros and the cons of the use of MSCs for the therapy of both type-1 and type-2 diabetes.
Donzelli, E., & Scuteri, A. (2020). Mesenchymal stem cells: A trump card for the treatment of diabetes?. BIOMEDICINES, 8(5).
|Citazione:||Donzelli, E., & Scuteri, A. (2020). Mesenchymal stem cells: A trump card for the treatment of diabetes?. BIOMEDICINES, 8(5).|
|Tipo:||Articolo in rivista - Review Essay|
|Carattere della pubblicazione:||Scientifica|
|Presenza di un coautore afferente ad Istituzioni straniere:||No|
|Titolo:||Mesenchymal stem cells: A trump card for the treatment of diabetes?|
|Autori:||Donzelli, E; Scuteri, A|
DONZELLI, ELISABETTA (Co-ultimo)
SCUTERI, ARIANNA (Co-ultimo) (Corresponding)
|Data di pubblicazione:||2020|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.3390/BIOMEDICINES8050112|
|Appare nelle tipologie:||01 - Articolo su rivista|